MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
Abstract
Purpose: Loss of cell-cycle control is a hallmark of cancer, which can be targeted with agents, including cyclin-dependent kinase-4/6 (CDK4/6) kinase inhibitors that impinge upon the G1–S cell-cycle checkpoint via maintaining activity of the retinoblastoma tumor suppressor (RB). This class of drugs is under clinical investigation for various solid tumor types and has recently been FDA-approved for treatment of breast cancer. However, development of therapeutic resistance is not uncommon.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 01, 2018
- Source ID
- 10.1158/1078-0432.ccr-18-0410
Entities
People
- Akihiro Yoshida
- Christopher Mcnair
- E. Starr Hazard
- Gary Hardiman
- J. Alan Diehl
- Justin M Drake
- Karen E. Knudsen
- Larry C Cheng
- Lucas J. Brand
- Maha H. Hussain
- Matthew J. Schiewer
- Michael A. Augello
- Neermala Poudel Neupane
- Renée De Leeuw
- Sean M. Courtney
- Wm. Kevin Kelly
- Zhen Li
Organizations
- Medical University of South Carolina
- National Institute of General Medical Sciences
- National Institutes of Health
- New Jersey Health Foundation
- Northwestern University
- Novartis
- Prostate Cancer Foundation
- Robert Wood Johnson Medical School
- Rutgers University
- Thomas Jefferson University
- United States Department of Defense